Stocktoria
Entera Bio Ltd. ENTX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-06-28
Entera Bio Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $42,000 | $181,000 | $0 | $134,000 | $571,000 |
| Gross profit | $0 | $9,000 | $0 | $33,000 | $198,000 |
| R&D expense | $6.0M | $4.5M | $4.5M | $5.8M | $6.8M |
| SG&A expense | $398,000 | $340,000 | — | — | — |
| Operating income | -$11.5M | -$9.6M | -$8.9M | -$13.0M | -$12.2M |
| Income tax | $0 | $14,000 | $29,000 | $137,000 | -$59,000 |
| Net income | -$11.4M | -$9.5M | -$8.9M | -$13.1M | -$12.2M |
| EPS (diluted) | $0.25 | $0.25 | $0.31 | $0.45 | $0.47 |
| Operating cash flow | -$7.4M | -$6.8M | -$7.3M | -$12.5M | -$9.1M |
| Free cash flow | -$7.5M | -$6.8M | -$7.3M | -$12.5M | -$9.1M |
| Cash & equivalents | $7.1M | $8.7M | $11.0M | $12.3M | $24.9M |
| Total assets | $16.0M | $9.4M | $11.8M | $13.1M | $26.0M |
| Total liabilities | $2.9M | $1.3M | $1.4M | $1.4M | $3.4M |
| Shareholders' equity | $13.1M | $8.1M | $10.4M | $11.8M | $22.6M |
Source: SEC EDGAR filings · CIK 0001638097 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.